SG59988A1
(en)
*
|
1987-09-04 |
1999-02-22 |
Beecham Group Plc |
Substituted thiazolidinedione derivatives
|
US5232925A
(en)
*
|
1987-09-04 |
1993-08-03 |
Beecham Group P.L.C. |
Compounds
|
US5194443A
(en)
*
|
1987-09-04 |
1993-03-16 |
Beecham Group P.L.C. |
Compounds
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
GB8919434D0
(en)
*
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US5053420A
(en)
*
|
1989-10-13 |
1991-10-01 |
Pershadsingh Harrihar A |
Thiazolidine derivatives for the treatment of hypertension
|
US5037842A
(en)
*
|
1990-06-05 |
1991-08-06 |
Pfizer Inc. |
Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
|
GB9017218D0
(en)
*
|
1990-08-06 |
1990-09-19 |
Beecham Group Plc |
Novel compounds
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
GB9023583D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
ATE144142T1
(de)
*
|
1991-01-10 |
1996-11-15 |
Transcend Therapeutics Inc |
Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
|
US5747459A
(en)
*
|
1991-02-04 |
1998-05-05 |
Nestec, Ltd. |
Method for insuring adequate intracellular glutathione in tissue
|
JP3053490B2
(ja)
*
|
1991-02-25 |
2000-06-19 |
杏林製薬株式会社 |
チアゾリジン−2,4−ジオン誘導体とその塩及び製造法
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
NO179246C
(no)
*
|
1991-11-20 |
1996-09-04 |
Sankyo Co |
Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
|
AU3959193A
(en)
*
|
1992-04-10 |
1993-11-18 |
Smithkline Beecham Plc |
Heterocyclic compounds and their use in the treatment of type II-diabetes
|
US5589492A
(en)
*
|
1992-04-10 |
1996-12-31 |
Smithkline Beecham Plc |
Heterocyclic compounds and their use in the treatment of Type-II diabetes
|
US5430045A
(en)
*
|
1992-04-23 |
1995-07-04 |
Free Radical Sciences, Inc. |
Method of reducing or preventing bone marrow hypoplasia
|
PL176885B1
(pl)
*
|
1992-07-03 |
1999-08-31 |
Smithkline Beecham Plc |
Kompozycja farmaceutyczna
|
US5326770A
(en)
*
|
1992-07-17 |
1994-07-05 |
The Du Pont Merck Pharmaceutical Company |
Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
|
US5306724A
(en)
*
|
1992-08-17 |
1994-04-26 |
Clintec Nutrition Company |
Method for preventing and treating atherosclerosis
|
EP0590793B1
(en)
*
|
1992-08-31 |
1999-10-13 |
Sankyo Company Limited |
Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
KR0173145B1
(ko)
*
|
1993-04-07 |
1999-02-01 |
고바야시 유키오 |
티아졸리딘 유도체 및 이를 함유하는 약학적 조성물
|
GB9308487D0
(en)
*
|
1993-04-23 |
1993-06-09 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311644D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311661D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9315148D0
(en)
*
|
1993-07-22 |
1993-09-08 |
Smithkline Beecham Plc |
Novel compounds
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
RU2195282C2
(ru)
*
|
1993-09-15 |
2002-12-27 |
Санкио Компани Лимитед |
Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm)
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5447712A
(en)
*
|
1993-12-09 |
1995-09-05 |
Free Radical Sciences |
Method of reducing cyclophosphamide induced hemorrhagic cystitis
|
US5480896A
(en)
*
|
1994-01-27 |
1996-01-02 |
American Home Products Corporation |
Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
|
JPH09512249A
(ja)
*
|
1994-02-10 |
1997-12-09 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
腎臓疾患を治療するためのインスリンセンシタイザーの使用
|
RU2114844C1
(ru)
*
|
1994-04-11 |
1998-07-10 |
Санкио Компани Лимитед |
Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
|
US5594015A
(en)
*
|
1994-06-22 |
1997-01-14 |
Regents Of The University Of California |
Thiazolidine derivatives for the treatment of psoriasis
|
US5703096A
(en)
*
|
1994-10-07 |
1997-12-30 |
Sankyo Company, Limited |
Oxime derivatives, their preparation and their therapeutic use
|
US5436373A
(en)
*
|
1994-10-26 |
1995-07-25 |
Elf Atochem North America, Inc. |
Process for the preparation of N-benzyl-N-organoaminoalkanol
|
US5641796A
(en)
*
|
1994-11-01 |
1997-06-24 |
Eli Lilly And Company |
Oral hypoglycemic agents
|
US5827865A
(en)
*
|
1995-03-09 |
1998-10-27 |
Smithkline Beecham P.L.C. |
Heterocyclic compounds as pharmaceutical
|
US5925656A
(en)
*
|
1995-04-10 |
1999-07-20 |
Dr. Reddy's Research Foundation |
Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
IL118474A
(en)
*
|
1995-06-01 |
2001-08-08 |
Sankyo Co |
Benzimideol derivatives and pharmaceutical preparations containing them
|
TWI238064B
(en)
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
US5798375A
(en)
*
|
1995-07-03 |
1998-08-25 |
Sankyo Company, Limited |
Treatment of arteriosclerosis and xanthoma
|
US5859051A
(en)
*
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
US5847008A
(en)
*
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
US6090836A
(en)
*
|
1996-02-02 |
2000-07-18 |
Merck & Co., Inc. |
Benzisoxazole-derived antidiabetic compounds
|
US6020382A
(en)
*
|
1996-02-02 |
2000-02-01 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
IL120443A
(en)
*
|
1996-03-18 |
2000-07-16 |
Sankyo Co |
Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
|
NZ332136A
(en)
*
|
1996-04-04 |
1999-08-30 |
Sankyo Co |
Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
|
EP0801063B1
(en)
*
|
1996-04-09 |
2003-01-15 |
Dr. Reddy's Laboratories Ltd. |
Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5919782A
(en)
*
|
1996-05-06 |
1999-07-06 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5801173A
(en)
*
|
1996-05-06 |
1998-09-01 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5889032A
(en)
*
|
1996-05-06 |
1999-03-30 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
ZA973850B
(en)
*
|
1996-05-06 |
1997-12-02 |
Reddy Research Foundation |
Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
|
AU3091197A
(en)
*
|
1996-05-16 |
1997-12-05 |
Boehringer Mannheim Gmbh |
New process for preparing troglitazone
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5885997A
(en)
*
|
1996-07-01 |
1999-03-23 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
US6114526A
(en)
|
1996-07-01 |
2000-09-05 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
BR9711098B1
(pt)
*
|
1996-07-01 |
2011-10-04 |
|
compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
|
US6372750B2
(en)
*
|
1996-07-01 |
2002-04-16 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
|
USRE39266E1
(en)
*
|
1996-07-01 |
2006-09-05 |
Dr. Reddy's Laboratories, Limited |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
WO1997041120A1
(en)
*
|
1996-07-26 |
1997-11-06 |
Dr. Reddy's Research Foundation |
Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
|
US6090839A
(en)
*
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
US6160000A
(en)
*
|
1996-12-23 |
2000-12-12 |
Merck & Co., Inc. |
Antidiabetic agents based on aryl and heteroarylacetic acids
|
UY24886A1
(es)
*
|
1997-02-18 |
2001-08-27 |
Smithkline Beecham Plc |
Tiazolidindiona
|
AU774839B2
(en)
*
|
1997-02-18 |
2004-07-08 |
Smithkline Beecham Plc |
Process for the preparation of substituted thiazolidinedione
|
EP1006794B1
(en)
*
|
1997-03-12 |
2007-11-28 |
Robert W. Esmond |
A method for treating or preventing alzheimer's disease
|
DE19711616A1
(de)
|
1997-03-20 |
1998-09-24 |
Boehringer Mannheim Gmbh |
Verbessertes Verfahren zur Herstellung von Thiazolidindionen
|
US6313113B1
(en)
|
1997-04-15 |
2001-11-06 |
Reddy-Cheminor, Inc. |
Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US6011031A
(en)
*
|
1997-05-30 |
2000-01-04 |
Dr. Reddy's Research Foundation |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
|
GB9711683D0
(en)
*
|
1997-06-05 |
1997-08-06 |
Smithkline Beecham Plc |
Composition
|
EP2266576A1
(en)
*
|
1997-06-18 |
2010-12-29 |
SmithKline Beecham Limited |
Treatment of diabetes with thiazolidinedione and sulphonylurea
|
PT996444E
(pt)
*
|
1997-06-18 |
2007-06-08 |
Smithkline Beecham Plc |
Tratamento de diabetes com tiazolidinodiona e metformina
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
BR9813019A
(pt)
|
1997-10-02 |
2000-09-05 |
Sankyo Co |
Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas
|
GB9721692D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
US20020006939A1
(en)
*
|
1997-10-13 |
2002-01-17 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
GB9721693D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
US20010031776A1
(en)
*
|
1997-10-13 |
2001-10-18 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
US7091359B2
(en)
|
1997-11-04 |
2006-08-15 |
Smithkline Beecham Plc |
Process for the preparation of thiazolidinedione derivatives
|
GB9723295D0
(en)
*
|
1997-11-04 |
1998-01-07 |
Smithkline Beecham Plc |
Novel process
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
JP4391597B2
(ja)
*
|
1997-12-02 |
2009-12-24 |
ドクター・レディーズ・ラボラトリーズ・リミテッド |
抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体
|
DE69824756T2
(de)
*
|
1997-12-02 |
2005-07-14 |
Dr. Reddy's Laboratories Ltd. |
Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
|
US6664278B2
(en)
|
1997-12-16 |
2003-12-16 |
Smithkline Beecham P.L.C. |
Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
|
GB9726566D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20020137940A1
(en)
*
|
1997-12-16 |
2002-09-26 |
Smithkline Beecham P.L.C. |
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
|
WO1999030739A1
(fr)
*
|
1997-12-16 |
1999-06-24 |
Sankyo Company, Limited |
Remede contre la leucemie
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB9726563D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
ATE274510T1
(de)
|
1998-06-19 |
2004-09-15 |
Chiron Corp |
Glycogen synthase kinase 3 inhibitoren
|
EP1098639B1
(en)
*
|
1998-07-21 |
2005-02-09 |
SmithKline Beecham plc |
Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
|
US6613785B2
(en)
|
1998-07-21 |
2003-09-02 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
|
MA26662A1
(fr)
*
|
1998-07-21 |
2004-12-20 |
Smithkline Beecham Plc |
Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
|
IN187716B
(da)
*
|
1998-09-14 |
2002-06-15 |
Reddy Research Foundation |
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
IL143002A0
(en)
|
1998-11-12 |
2002-04-21 |
Smithkline Beecham Plc |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
DZ2937A1
(fr)
*
|
1998-11-12 |
2004-03-15 |
Smithkline Beecham Plc |
Compositions nouvelles de sensibilidants à l'insuline.
|
CA2350599A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
AU3073700A
(en)
*
|
1999-01-19 |
2000-08-07 |
Sankyo Company Limited |
Troglitazone-containing medicinal compositions for inhibiting apoptosis
|
GB9909041D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB9909075D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
UA67845C2
(uk)
*
|
1999-04-23 |
2004-07-15 |
Smithkline Beecham Plc |
Поліморф 5-[4-[2- (n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
|
AU765498B2
(en)
|
1999-04-23 |
2003-09-18 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
NZ515168A
(en)
|
1999-04-23 |
2004-02-27 |
Smithkline Beecham Plc |
Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
|
US20040248945A1
(en)
|
1999-04-23 |
2004-12-09 |
Smithkline Beecham P.L.C. |
Thiazolidinedione derivative and its use as antidiabetic
|
AU4314000A
(en)
|
1999-04-28 |
2000-11-17 |
Institute Of Medicinal Molecular Design. Inc. |
Heterocyclic carboxylic acid derivatives
|
GB9913782D0
(en)
*
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
EP1194147B1
(en)
*
|
1999-06-18 |
2007-01-10 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
CA2381976A1
(en)
*
|
1999-08-17 |
2001-02-22 |
Michael Urquhart |
Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
AR030920A1
(es)
*
|
1999-11-16 |
2003-09-03 |
Smithkline Beecham Plc |
Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
|
ES2156574B1
(es)
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
RU2256661C2
(ru)
|
1999-12-03 |
2005-07-20 |
Киото Фармасьютикал Индастриз, Лтд. |
Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
|
HU225919B1
(en)
*
|
1999-12-18 |
2007-12-28 |
Richter Gedeon Nyrt |
Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
|
ATE346613T1
(de)
|
2000-01-21 |
2006-12-15 |
Novartis Pharma Gmbh |
Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
|
GB0006133D0
(en)
*
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6958355B2
(en)
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6680387B2
(en)
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6768008B2
(en)
*
|
2000-04-24 |
2004-07-27 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
EP1284291A4
(en)
*
|
2000-05-25 |
2005-06-08 |
Yamanouchi Pharma Co Ltd |
PROMOTER OF HUMAN PGC-1
|
GB0014005D0
(en)
*
|
2000-06-08 |
2000-08-02 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
GB0019228D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0019223D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021865D0
(en)
*
|
2000-09-06 |
2000-10-18 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021978D0
(en)
|
2000-09-07 |
2000-10-25 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO2002024689A1
(en)
|
2000-09-21 |
2002-03-28 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis
|
SK3752003A3
(sk)
*
|
2000-09-26 |
2005-03-04 |
Dr. Reddy's Laboratories Limited |
Polymorfné formy 5-[4[2-[N-metyl-N-(2- pyridyl)aminol]etoxy]benzyl]tiazolidín-2,4-dión maleátu a spôsob ich prípravy
|
US7241895B2
(en)
|
2000-09-26 |
2007-07-10 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
|
GB0023970D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0023971D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0029125D0
(en)
*
|
2000-11-29 |
2001-01-10 |
Specialistkliniken I Varberg H |
Novel treatment
|
EP1349855B1
(en)
|
2000-12-22 |
2006-08-23 |
Smithkline Beecham Plc |
5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione mesylate salt
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
WO2002051823A1
(en)
|
2000-12-26 |
2002-07-04 |
Torrent Pharmaceuticals Ltd |
Process for the preparation of rosiglitazone maleate
|
WO2002051441A1
(fr)
*
|
2000-12-26 |
2002-07-04 |
Sankyo Company, Limited |
Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
|
ES2174748B1
(es)
*
|
2001-01-31 |
2003-09-16 |
Vita Lab |
Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
|
JP4590159B2
(ja)
*
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
AU2002308891B2
(en)
*
|
2001-05-29 |
2007-09-06 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic derivatives and medicinal use thereof
|
EP1403253A4
(en)
*
|
2001-05-29 |
2005-03-30 |
Kyoto Pharma Ind |
NEW HETEROCYCLIC CONNECTION AND THEIR MEDICAL USE
|
JP4152641B2
(ja)
*
|
2001-08-07 |
2008-09-17 |
クラシエ製薬株式会社 |
チアゾリジン誘導体の副作用軽減剤
|
WO2003029251A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Biocon Limited |
Novel process for the synthesis of thiazolidinedione derivatives
|
GB0127805D0
(en)
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
WO2003050116A1
(en)
*
|
2001-12-13 |
2003-06-19 |
Smithkline Beecham Plc |
A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
|
GB0129872D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129876D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129871D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129851D0
(en)
*
|
2001-12-13 |
2002-01-30 |
Smithkline Beecham Plc |
Novel compounds
|
AU2002350965A1
(en)
*
|
2001-12-13 |
2003-06-23 |
Smithkline Beecham Plc |
Toluenesulfonate hydrates of a thiazolidinedione derivative
|
GB0130509D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
AU2002366812A1
(en)
*
|
2001-12-20 |
2003-07-09 |
Teva Pharmaceutical Industries Ltd. |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
GB0130510D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO2003053962A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Smithkline Beecham Plc |
5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
|
GB0130511D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
CA2482857A1
(en)
*
|
2002-04-29 |
2003-11-13 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing losartan and losartan potassium
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
EP1388352A1
(en)
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
US7687625B2
(en)
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2004089945A1
(en)
*
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Rosiglitazone derivatives as antidiabetic agents
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
WO2004106542A1
(ja)
*
|
2003-05-29 |
2004-12-09 |
Sankyo Company, Limited |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
CA2753318A1
(en)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives
|
FR2858556B1
(fr)
*
|
2003-08-06 |
2006-03-10 |
Galenix Innovations |
Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
|
CN1867560A
(zh)
|
2003-08-13 |
2006-11-22 |
武田药品工株式会社 |
4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
WO2005023803A1
(en)
*
|
2003-09-10 |
2005-03-17 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
|
JP5140881B2
(ja)
*
|
2003-09-17 |
2013-02-13 |
要 川杉 |
医薬組成物
|
US20050163837A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Rosiglitazone formulations
|
WO2005065663A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Alpharma, Inc. |
Rosiglitazone and metformin formulations
|
EP1709038A2
(en)
*
|
2004-01-28 |
2006-10-11 |
Usv Limited |
A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
|
GB2410948A
(en)
*
|
2004-02-13 |
2005-08-17 |
Sandoz Ag |
Novel phosphoric acid salt of rosiglitazone
|
AR047541A1
(es)
*
|
2004-02-13 |
2006-01-25 |
Sandoz Ag |
Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
|
GB2421240A
(en)
*
|
2004-12-14 |
2006-06-21 |
Sandoz Ag |
Phosphoric acid salt of rosiglitazone
|
CN102079743B
(zh)
*
|
2004-03-15 |
2020-08-25 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2005092382A1
(ja)
*
|
2004-03-29 |
2005-10-06 |
Sankyo Company, Limited |
インスリン抵抗性改善剤を含有する糖尿病治療剤
|
GB2413795A
(en)
*
|
2004-05-05 |
2005-11-09 |
Cipla Ltd |
Process for the preparation of rosiglitazone
|
EP1745043A1
(en)
*
|
2004-05-12 |
2007-01-24 |
Medichem S.A. |
Process for the preparation of rosiglitazone
|
CZ296468B6
(cs)
*
|
2004-06-10 |
2006-03-15 |
Zentiva, A. S. |
Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
CZ297266B6
(cs)
*
|
2004-09-10 |
2006-10-11 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
CZ297347B6
(cs)
*
|
2004-09-21 |
2006-11-15 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
US20070190079A1
(en)
*
|
2004-10-29 |
2007-08-16 |
Kalypsys, Inc. |
Methods for the selective modulation of ppar
|
US20060122232A1
(en)
*
|
2004-12-06 |
2006-06-08 |
Development Center For Biotechnology |
4-Hydroxyfuroic acid derivatives
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
CZ298424B6
(cs)
*
|
2005-05-24 |
2007-09-26 |
Zentiva, A. S. |
Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
|
FR2887442A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
|
FR2887444A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
|
TW200740460A
(en)
*
|
2005-07-12 |
2007-11-01 |
Sankyo Co |
Pharmaceutical composition containing PPAR γ agonist
|
DK1942898T4
(da)
*
|
2005-09-14 |
2014-06-02 |
Takeda Pharmaceutical |
Dipeptidylpeptidase-inhibitorer til behandling af diabetes
|
KR101368988B1
(ko)
*
|
2005-09-16 |
2014-02-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
디펩티딜 펩티다제 억제제
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
US8026377B2
(en)
*
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
CA2645189A1
(en)
*
|
2006-03-08 |
2008-01-24 |
Medichem, S.A. |
Process for preparation of intermediates of rosiglitazone, rosiglitazone and new polymorphic forms thereof
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
JP2009531456A
(ja)
*
|
2006-03-28 |
2009-09-03 |
武田薬品工業株式会社 |
(r)−3−アミノピペリジン二塩酸塩の調製
|
WO2007117791A2
(en)
*
|
2006-03-31 |
2007-10-18 |
Wellstat Therapeutics Corporation |
Combination treatment of metabolic disorders
|
US7435741B2
(en)
*
|
2006-05-09 |
2008-10-14 |
Teva Pharmaceutical Industries, Ltd. |
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
|
DE202006020710U1
(de)
|
2006-05-09 |
2009-12-31 |
Teva Pharmaceutical Industries Ltd. |
Zusammensetzungen mit Rosiglitazonmaleat
|
US20070293546A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Srinivasula Reddy Maddula |
Preparation of rosiglitazone and its salts
|
HUP0600517A3
(en)
*
|
2006-06-23 |
2008-10-28 |
Richter Gedeon Nyrt |
Process for the production of benzylidene-rosiglitazone base
|
EP2452683A3
(en)
|
2006-06-26 |
2012-08-22 |
Amgen Inc. |
Methods for treating atherosclerosis
|
TW200811101A
(en)
*
|
2006-07-14 |
2008-03-01 |
Ranbaxy Lab Ltd |
Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
|
EP2063890A1
(en)
|
2006-09-07 |
2009-06-03 |
Nycomed GmbH |
Combination treatment for diabetes mellitus
|
AU2007296556B2
(en)
*
|
2006-09-13 |
2013-09-19 |
Takeda Pharmaceutical Company Limited |
Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP2010513324A
(ja)
|
2006-12-21 |
2010-04-30 |
アルファファーム ピーティーワイ リミテッド |
医薬化合物および医薬組成物
|
WO2008091624A2
(en)
*
|
2007-01-22 |
2008-07-31 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
|
EP1988091B1
(en)
|
2007-02-07 |
2015-06-10 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
JP5294419B2
(ja)
*
|
2007-04-05 |
2013-09-18 |
第一三共株式会社 |
縮合二環式ヘテロアリール誘導体
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
UA103304C2
(ru)
|
2007-07-26 |
2013-10-10 |
Эмджен Инк. |
Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
|
US20090076093A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched rosiglitazone
|
PL384446A1
(pl)
*
|
2008-02-12 |
2009-08-17 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
JP5559689B2
(ja)
|
2008-08-06 |
2014-07-23 |
協和発酵キリン株式会社 |
3環系化合物
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
JP5833922B2
(ja)
|
2008-08-12 |
2015-12-16 |
ジンファンデル ファーマシューティカルズ インコーポレイテッド |
疾患危険因子を同定する方法
|
EP2184055A1
(en)
|
2008-11-07 |
2010-05-12 |
LEK Pharmaceuticals d.d. |
Process for preparing solid dosage forms of rosiglitazone maleate
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
HUP0800755A2
(en)
|
2008-12-11 |
2010-09-28 |
Richter Gedeon Nyrt |
Crystalline forms of rosiglitazone
|
EP2404918B1
(en)
|
2009-03-05 |
2016-11-30 |
Daiichi Sankyo Company, Limited |
Pyridine derivative as ppary inhibitor
|
DE102009053562A1
(de)
|
2009-11-18 |
2011-05-19 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
JPWO2012033091A1
(ja)
|
2010-09-07 |
2014-01-20 |
第一三共株式会社 |
安息香酸エステル類の製造法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20120094959A1
(en)
|
2010-10-19 |
2012-04-19 |
Bonnie Blazer-Yost |
Treatment of cystic diseases
|
EP2665479B1
(en)
|
2011-01-10 |
2019-06-26 |
Zinfandel Pharmaceuticals, Inc. |
Methods and drug products for treating alzheimer's disease
|
KR20140051998A
(ko)
|
2011-08-03 |
2014-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
디벤조옥세핀 유도체
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
DK2914250T3
(da)
|
2012-11-05 |
2018-06-18 |
Commissariat Energie Atomique |
Kombination af et anticancermiddel såsom en tyrosinkinasehæmmer og en stat5-antagonist, fortrinsvis et thiazolidindion til eliminering af hæmatologiske cancerstamceller in vivo og til forebyggelse af recidiv af hæmatologisk cancer
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CN113388007A
(zh)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
WO2015054500A2
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
US10111880B2
(en)
|
2013-11-05 |
2018-10-30 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
EP3568134A1
(en)
|
2017-01-16 |
2019-11-20 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
|
GR1010570B
(el)
*
|
2022-12-22 |
2023-11-17 |
Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., |
4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης
|